3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015) - Barlesi, F.; Dingemans, A.M.C.; Ou, I.; Ahn, J.S.; Petris, L.D.; Kim, D.W.; Yang, J.C.H.; Hughes, B.; Lena, H.; Moro-Sibilot, D.; Bearz, A.; Viteri, S.; et al.